Conference Coverage

Cancer-related clinical pearls from pediatric dermatology


 

EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR

D. folliculitis in immunocompromised patients

“The clinical pearl here is to strongly consider the diagnosis of Demodex folliculitis in an immunosuppresed patient with an itchy acneiform eruption,” Dr. Huang said.

Demodex is a human mite which is part of the normal skin flora. She called it “a great mimicker”: It can cause dermatoses mistaken for rosacea, acne, seborrheic dermatitis, perioral facial dermatitis, blepharitis, and acute graft-versus-host disease.

In the setting of a young, immunosuppressed patient who develops an acneiform eruption, the differential diagnosis is lengthy and includes steroid-induced acne, a cutaneous reaction to targeted anticancer therapy, gram-negative folliculitis secondary to long-term antibiotic therapy, and Pityrosporum folliculitis, as well as D. folliculitis.

Demodex and P. folliculitis are the two acneiform dermatoses where itch figures prominently. A couple of clues are helpful in differentiating the two conditions: P. folliculitis often involves the chest and back, while D. folliculitis generally spares the trunk and is focused on the face and neck. And D. folliculitis typically arises when immunosuppression is weaned. Overgrowth of the mites occurs during immunosuppression, then as the immunosuppression is lifted a prominent inflammatory response with an acne-like appearance occurs.

Pages

Recommended Reading

Xenon imaging could detect lung involvement after HSCT
MDedge Hematology and Oncology
Protocol helped identify hospitalized children at risk for VTE
MDedge Hematology and Oncology
Melanoma in young children may be biologically distinct from that in teens
MDedge Hematology and Oncology
Team maps genetic evolution of T-ALL subtype
MDedge Hematology and Oncology
Drug nets orphan designation for SCD
MDedge Hematology and Oncology
Disease, genetics contribute to neurocognitive decline in ALL
MDedge Hematology and Oncology
Phase 1 results with UCART19 in kids
MDedge Hematology and Oncology
CHMP supports expanded approval for fosaprepitant
MDedge Hematology and Oncology
FDA approves nilotinib for kids with CML
MDedge Hematology and Oncology
Kids may have higher rate of AdV infection after HSCT
MDedge Hematology and Oncology